Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

Human Gene Therapy

Volumn 7, Issue 16, 1996, Pages 1955-1963

  Arienti, Flavio ^a   Sulé Suso, Josep ^a   Belli, Filiberto ^a   Mascheroni, Luigi ^a   Rivoltini, Licia ^a   Melani, Cecilia ^a   Maio, Michele ^b   Cascinelli, Natale ^a   Colombo, Mario P ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ERYTHEMA; FEMALE; FEVER; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA CELL; MIXED LYMPHOCYTE CULTURE; PERIPHERAL LYMPHOCYTE; TUMOR IMMUNITY;

EID: 19244363863     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.16-1955     Document Type: Article

References (29)

1. ANICHINI, A., MORTARINI, R., MACCALLI, C., SQUARCINA, P., FLEISCHHAUER, K., MASCHERONI, L., and PARMIANI, G. (1996). Cytotoxic T-cells directed to tumor antigens not expressed on normal melanocytes dominate the HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156, 208-217.
2. ARIENTI, F., SULE'-SUSO, J., MELANI, C., MACCALLI, C., BELLI, F., ILLENI, M.T., ANICHINI, A., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1994). Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5, 1139-1150.
3. BARTH, A., HOON, D.S.B., FOSHAG, L.J., NIZZE, J.A., FAMATIGA, E., OKUN, E., and MORTON, D.L. (1994). Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 54, 3342-3345.
4. BOON, T., GAJEWSKI, T.F., and COULIE, P. (1995). From defined human tumor antigens to effect immunization? Immunol. Today 16, 334-336.
5. COULIE, P.G., SOMVILLE, M., LEHMANN, F., HAINAULT, P., BRASSEUR, F., DEVOS, R., and BOON, T. (1992). Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50, 289-297.
6. CROWLEY, N.J., VERVAERT, C.E., and SEIGLER, H.F. (1992). Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. Cancer Res. 52, 394-399.
7. DARROW, T.L., SLINGLUFF, C.L., and SEIGLER, H.F. (1989). The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J. Immunol. 142, 3329-3335.
8. FERRONE, S., and MARINCOLA, F.M. (1995). Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494.
9. FLEISCHHAUER, K., TANZARELLA, S., WALLNY, H., BORDIGNON, C., and TRAVERSARI, C. (1996). Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A0201 cytotoxic T cell line. J. Immunol. (in press).
10. HARA, I., NGUYEN, H., TAKECHI, Y., GANSBACHER, B., CHAPMAN, P.B., and HOUGHTON, A.N. (1995). Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T-cells or natural killer cells in tumor rejection. Int. J. Cancer 61, 253-260.
11. + melanoma-infiltrating lymphocytes. Eur. J. Immunol. 25, 2732-2736.
12. MAASS, G., SCHMIDT, W., BERGER, M., SCHILCHER, F., KOSZIK, F., SCHNEEBERGER, A., STINGL, G., BIRNSTIEL, M.L., and SCHWEIGHOFFER, T. (1995). Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92, 5540-5544.
13. MARINCOLA, F.M., HIJAZI, Y., FETCH, P., SALGALLER, M.L., RIVOLTINI, L., CORMIER, J., KAWAKAMI, Y., and ROSENBERG, S.A. (1996). Analysis of tissue expression of the melanoma associated antigen MART-1 and GP-100 in metastatic melanoma. J. Immunother (in press).
14. p in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer 58, 330-339.
15. MORTON, D.L., FOSHAG, L.J., HOON, D.S.B., NIZZE, J.A., WANEK, L.A., CHANG, C., DAVTYAN, D.G., GUPTA, R.K., ELASHOFF, R., and IRIE, R.F. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463-482.
16. NATALI, P.G., NICOTRA, M.R., BIGOTTI, A., VENTURO, I., MERCENARO, L., GIACOMINI, P., and RUSSO, C. (1989). Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA 86, 6719-6723.
17. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
18. PARMIANI, G., and COLOMBO, M.P. (1995). Somatic gene therapy of human melanoma: pre-clinical studies and early clinical trials. Mel. Res. 5, 295-301.
19. PARMIANI, G., COLOMBO, M.P., MELANI, C., and ARIENTI, F. (1996). Cytokine gene-transduction in the immunotherapy of cancer. Adv. Pharmacol. (in press).
20. PORGADOR, A., GANSBACHER, B., BANNERJI, R., TZEHOVAL, E., GILBOA, E., FELDMAN, M., and EISENBACH, L. (1993). Anti-metastatic vaccination of tumor-bearing mice with IL-2 gene-inserted tumor cells. Int. J. Cancer. 53, 471-477.
21. RIVOLTINI, L., LOFTUS, D.J., BARRACCHINI, K., ARIENTI, F., MAZZOCCHI, A., BIDDISON, W.E., SALGALLER, M.L., APPELLA, E., PARMIANI, G., and MARINCOLA, F.M. (1996). Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J. Immunol. 156, 3882-3891.
22. SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., MANCINI, M., and ROSENBERG, S.A. (1991). Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146, 3674-3681.
23. STEVENS, E.J., JACKNIN, L., ROBBINS, P.F., KAWAKAMI, Y., EL-GAMIL, M., ROSENBERG, S.A., and YANNELLI, J.R. (1995). Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154, 762-771.
24. TAKAHASHI, T., CHAPMAN, P.B., YANG, S.Y., HARA, I., VIJAYASARADHI, S., and HOUGHTON, A.N. (1995). Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154, 772-779.
25. TOPALIAN, S.L., RIVOLTINI, L., MANCINI, M., MARKUS, N.R., ROBBINS, P.F., KAWAKAMI, Y., and ROSENBERG, S.A. (1994). Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91, 9461-9465.
26. UCHIYAMA, A., HOON, D.S.B., MORISAKI, T., KANEDA, Y., YUZUKI, D.H., and MORTON, D.L. (1993). Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response. Cancer Res. 53, 949-952.
27. VAN ELS, C.A.C.M., D'AMARO, J., POOL, J., BLOKLAND, E., BARKER, A., VAN ELSEN, P.J., VAN ROOD, J.J., and GOULMY, E. (1992). Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 35, 161-165.
28. YANNELLI, J.R., HYATT, C., JOHNSON, S., HWU, P. and ROSENBERG, S.A. (1993). Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor α (TNF-α) or interleukin-2 (IL-2). J. Immunol. Meth. 161, 77-90.
29. ZATLOUKAL, K., SCHNEEBERGER, A., BERGER, M., SCHMIDT, W., KOSZIK, F., KUTIL, R., COTTEN, M., WAGNER, E., BUSCHLE, M., MAASS, G., PAYER, E., STINGL, G., and BIRNSTIEL, M.L. (1995). Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J. Immunol. 154, 3406-3419.